Quality-of-Life Assessment + NIVOLUMAB + IPILIMUMAB for adenocarcinoma of lung

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 29 Dec 2017: Trial started, NCT03391869
  2. 5 Jan 2018: Trial registered, NCT03391869

The trials

NCT03391869: Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

State
Under way
Phase
Phase 3
People
339 taking part
Started
29 Dec 2017
Primary completion
31 Mar 2027
Arms
Arm A (ipilimumab, nivolumab)
Results
None posted
  1. 29 Dec 2017: Trial started
  2. 5 Jan 2018: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.